Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00024622
Status:
RECRUITING
Last Update Posted:
2024-07-15
First Post:
2001-09-23
Brief Title:
PET Scanning in Parkinson s Disease
Sponsor:
National Institute of Mental Health NIMH
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Positron Emission Tomography PET Scanning in Dopamine Disorders Parkinsons Disease and Schizophrenia
Status:
RECRUITING
Status Verified Date:
2024-09-20
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an in vivo positron emission tomography PET study of regional cerebral dopamine and blood flow in normal volunteers persons with Parkinson s disease both familial and sporadic and those with schizophrenia spectrum disorders The latter also sign consent for NIH approved protocol 89-M-0160 Inpatient Evaluation of Neuropsychiatric Patients PI Daniel Eisenberg MD Using PET with 6-F-18 Fluoro-L-dopa FDOPA and 150-H2O in a single scan session both presynaptic dopaminergic function and regional cerebral blood flow rCBF are assessed The kinetic rate constant Ki for presynaptic dopaminergic uptake in striatum and other regions is calculated We compare Ki across subject groups and relate the findings to rCBF Findings are also related to allelic variation in genes of interest for determination of which participants sign separate consent for NIH approved protocol 95-M-0150 Neurobiological Investigation of Patients with Schizophrenia Spectrum Disorders and Their Siblings PI Karen F Berman MD We also draw comparisons between subjects with inherited vs sporadic Parkinson s disease to determine whether the PET phenotype is the same in both groups and we compare system-level circuit-based pathophysiology across PD and schizophrenia groups Each subject is further screened with an MRI to rule out structural abnormalities and also to further delineate areas of interest in the PET scans
Detailed Description:
This is an in vivo positron emission tomography PET study of regional cerebral dopamine and blood flow in normal volunteers persons with Parkinson s disease both familial and sporadic and those with schizophrenia spectrum disorders The latter also sign consent for NIH approved protocol 89-M-0160 Inpatient Evaluation of Neuropsychiatric Patients PI Daniel Eisenberg MD Using PET with 6-F-18 Fluoro-L-dopa FDOPA and 150-H2O in a single scan session both presynaptic dopaminergic function and regional cerebral blood flow rCBF are assessed The kinetic rate constant Ki for presynaptic dopaminergic uptake in striatum and other regions is calculated We compare Ki across subject groups and relate the findings to rCBF Findings are also related to allelic variation in genes of interest for determination of which participants sign separate consent for NIH approved protocol 95-M-0150 Neurobiological Investigation of Patients with Schizophrenia Spectrum Disorders and Their Siblings PI Karen F Berman MD We also draw comparisons between subjects with inherited vs sporadic Parkinson s disease to determine whether the PET phenotype is the same in both groups and we compare system-level circuit-based pathophysiology across PD and schizophrenia groups Each subject is further screened with an MRI to rule out structural abnormalities and also to further delineate areas of interest in the PET scans
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 01-M-0232 | None | None | None |